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Background. Acetaminophen is often used with a non-steriodal anti-inﬂammatory drug for
acute pain. Hitherto, these drugs have had to be given separately, typically at different time
intervals. Maxigesic
w tablets combine acetaminophen and ibuprofen in clinically appropriate
doses to simplify administration and dosage regimen. We compared this combination with each
of the constituent drugs for the relief of pain after extraction of third molar teeth.
Methods. Adults (more than 16 yr) having one or more wisdom teeth removed under general
or local anaesthesia were instructed to take two tablets before operation, then two tablets
every 6 h for up to 48 h of: (i) a combination of acetaminophen 500 mg and ibuprofen 150 mg
per tablet (Maxigesic
w); (ii) acetaminophen 500 mg per tablet alone; or (iii) ibuprofen 150 mg
per tablet alone. The primary outcome measure was the area under the curve (AUC) of the
100 mm visual analogue scale pain measurements taken for up to 48 h after surgery, divided by
time, at rest and on activity. Pharmacokinetic data were collected in a subset of patients.
Results. The mean (SEM) time-corrected AUC on rest and activity, respectively, were: combi-
nation group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibu-
profen group 34.8 (3.2) and 40.2 (3.4); P,0.01 for each of the four comparisons of combination
vs constituent drug. There was no pharmacokinetic interaction between acetaminophen and
ibuprofen administered together.
Conclusions. Maxigesic
w tablets provide superior pain relief after oral surgery to acetamino-
phen or ibuprofen alone.
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The relief of pain has been described as a universal human
right but is not always easily achieved.
1 Opioid analgesics
are effective, but have troublesome and potentially danger-
ous side-effects, and their potential for abuse may lead to
regulatory and logistical difﬁculties. Non-steroidal anti-
inﬂammatory drugs (NSAIDs) have fewer regulatory
restrictions, but they too have important adverse effects
which are more likely at higher dose or with longer
courses.
2 Acetaminophen is widely used and is very safe
at the recommended dose of 4 g per day,
3 but does not
always provide adequate pain relief on its own. Combining
analgesics offers the possibility of increasing effectiveness
without increasing dose (and therefore risk).
45NSAIDs
are often combined with acetaminophen, particularly for
treating postoperative pain.
6–10
Prescribing acetaminophen and ibuprofen together is
common in clinical practice.
6891 1 – 1 3Ibuprofen has the
advantage of a well-established safety record (particularly
at doses below 1.5 g per day in adults),
14 and in many
countries (including the UK), it is available without
# The Author [2010]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
British Journal of Anaesthesia 104 (1): 80–8 (2010)
doi:10.1093/bja/aep338prescription. Typically, acetaminophen is given in a dose
regimen of 1 g 6 hourly whereas ibuprofen is given in a
dose of 400 mg 8 hourly.
3 Compliance with the prescribed
dosing regimen is important for achieving the desired
result with any drug and is often poor with asynchronous
dosing.
15 A single formulation with a simpliﬁed regimen
would probably be appreciated by patients and might
improve compliance.
Maxigesic
w is a new formulation of acetaminophen 500
mg and ibuprofen 150 mg. Taking two tablets 6 hourly
provides the appropriate daily dose of both drugs relatively
simply. We have investigated the hypothesis that in adult
patients undergoing a common surgical procedure (extrac-
tion of third molar teeth), this formulation provides
superior analgesia to either of its components alone.
Methods
With ethics committee approval, we recruited and fol-
lowed up patients between March 2005 and February
2008. Trial registration: ANZCTR.ORG.AU (identiﬁer:
ACTRN12606000291583).
Setting
This study was conducted at a publicly funded teaching
hospital and a private day-surgical clinic in metropolitan
New Zealand.
Participants
We included adults undergoing extraction of at least one
lower wisdom tooth with or without one or more upper
wisdom teeth by one of three participating surgeons. We
excluded patients if they were under 16 yr old; weighed
,50 kg; had taken any NSAID (other than aspirin in a
dose of 150 mg daily or less) within 24 h of the operation;
had taken acetaminophen or acetaminophen containing
medicines within 12 h of the operation; were taking an
angiotensin-converting enzyme inhibitor, warfarin, steroid
(other than interoperative dexamethasone), or any immu-
nosuppressive drug; were intolerant to any NSAID or acet-
aminophen; were suffering from a severe local infection;
had a history of peptic ulceration, asthma, or severe hae-
mopoetic, renal or hepatic disease; were participating in
the investigation of another experimental agent; or if the
clinician believed for any other reason that participation in
the study might not be in their best interests.
Randomization and blinding
Tablets of identical appearance, packaging, and dosage
instructions were provided in each of the following formu-
lations: (i) acetaminophen 500 mgþibuprofen 150 mg per
tablet (Maxigesic
w; Sigma Laboratories, Nashik, India which
was MHRA approved for manufacturing pharmaceuticals
under GMP); (ii) acetaminophen 500 mg per tablet; or
(iii) ibuprofen 150 mg per tablet.
Patients were ﬁrst approached by the surgeon and then
by the study nurse. They were given written and verbal
information about the study, and invited to participate. If
they consented, patients were then randomized into one of
the three study groups in a sequential order to receive one
of these formulations, in blinded packs. The randomization
sequence was computer generated by the study statistician
as a 1:1:1 allocation ratio to the three treatments in a
sequence of permuted blocks with stratiﬁcation for anaes-
thetic type (local or general) and study centre.
Stratiﬁcation by anaesthetic type ensured a balance
between treatments in terms of the number of teeth
extracted, as most patients having more than two teeth
extracted have a general anaesthetic. Only the statistician
had access to the schedule of patient numbers by drug
allocation. Participants and investigators were blinded and
the randomization code was not broken until the ﬁnal data-
base had been checked and locked.
Intervention
Participants were asked to take two tablets of the study
medication before operation (as close as possible to the
start of surgery) and then 4 times a day (as close as poss-
ible to 6 hourly) for up to 48 h after surgery. All partici-
pants were given bupivacaine local anaesthetic blocks by
the surgeons. For those participants undergoing general
anaesthesia, this was induced with propofol and main-
tained with isoﬂurane and nitrous oxide in oxygen.
Monitoring was in accordance with the guidelines of the
Australian and New Zealand College of Anaesthetists.
16
All extractions were carried out by one of three surgeons,
each using his normal technique.
If participants required additional postoperative pain
relief while in hospital, a rescue dose of fentanyl 10 mg
was given i.v., as required. After discharge to home,
codeine was provided (again, as rescue medication) in 30
mg tablets, one to two to be taken as needed up to
4 hourly.
Outcomes
Participants were asked to rate their pain on 100 mm visual
analogue scales (VAS), printed one per double page in a
booklet that they took home. Ratings were requested at
baseline (immediately before administration of the ﬁrst
dose of study medication); after operation (once the partici-
pants were sufﬁciently awake to respond); and 1–2 hourly
thereafter, while awake, for 48 h. The study nurse main-
tained contact with participants by telephone to facilitate
compliance with data collection and the return of diaries.
The primary outcome measure was the area under the
curve (AUC) of these VAS ratings divided by time, at rest
and on activity. The AUC was divided by the period of
the completed assessments to adjust for the fact that some
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81patients recorded pain for shorter periods than others. This
calculation in effect produces a measure of average pain
intensity over the study period.
Secondary efﬁcacy outcome measures were: a categorical
global pain rating by the participants, taken at the end of the
study period; rescue analgesia consumption over the study
period; a categorical global rating of nausea by the partici-
pants, taken at the end of study period; the number of epi-
sodes of vomiting over the study period; and a rating of
sleep disturbance on a 100 mm VAS assessed after each
night during the study period. In addition, participants were
asked to rate their experiences of participating in the study.
Sample size estimation
We obtained blood samples from the 38 participants
undergoing general anaesthesia in order to have evaluable
pharmacokinetic data for at least 30 patients. The ﬁrst
sample was obtained 30 min after the ﬁrst dose of study
medication, the second sample at the end of anaesthesia,
and additional one or two samples after operation in hospi-
tal. The plasma concentration of acetaminophen and ibu-
profen were measured by the sponsor and used to form
individual time–concentration proﬁles. The analytical
method used an HPLC-DAD (Diode Array Detector) assay
for the simultaneous determination of acetaminophen and
ibuprofen in plasma. Precision and accuracy for acetami-
nophen and ibuprofen assay were validated over the con-
centration range 0.5–50 mgm l
21 for both drugs. The
intra- and inter-batch precision of the assays at low,
medium, and high concentrations of acetaminophen and
ibuprofen varied from theoretical values by ,15%. The
lower limit of quantiﬁcation for each drug was 0.5 mg
ml
21. The sponsor monitored all data collected during the
study and queries and corrections were made when any
inaccuracies or inconsistencies were identiﬁed.
Sample size estimation
We estimated that 120 participants (40 per group) in the
intention-to-treat (ITT) population would provide 80%
power to detect differences between the groups of 9 (SD
14) mm in our primary endpoint for resting assessments
and 13 (SD 21) for measures during activity,
10 17 with a
one-sided type I error rate of 5%. These differences equate
to  25%. Differences of this magnitude were considered
clinically important and comparable with differences
typical of previous published studies.
10
Statistical methods
The data were analysed using SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA). Efﬁcacy analyses were conducted
on an ITT basis with the additional provision that
there were at least three VAS measurements over at
least 12 h available to calculate the primary endpoint. All
participants who were randomized into the study were
included in the safety evaluations. As the ﬁrst dose of
study medication was taken before operation while under
the supervision of the surgeon, all randomized patients
took at least a single dose of study medication. A last
observation carried forward approach was used for those
subjects who left the study prematurely for non-AUC
based variables.
We compared the primary endpoint between the combi-
nation group and each of the acetaminophen and ibuprofen
arms, at rest and on activity, using a general linear model
(GLM) which included terms for treatment, the centre, and
anaesthetic stratum. Additionally, to conﬁrm the consist-
ency of the treatment effects across strata, the stratum
treatment interaction terms were tested and included in
the ﬁnal model. The analysis was also checked with
number of teeth extracted as an additional factor.
Continuous secondary efﬁcacy endpoints were tested for
signiﬁcance using the same models as used for the
primary endpoint.
A one-tailed P 0.05 was pre-speciﬁed to indicate stat-
istical signiﬁcance. We required a statistically signiﬁcant
result favouring the combination from each of the two
planned comparisons with the constituents to deﬁne super-
iority for either rest or on activity measures. We used one-
tailed tests as there seemed no theoretical or empirical
basis for expecting that combining these analgesics could
result in a reduction in efﬁcacy, and because the require-
ment for each of two comparisons to be signiﬁcant at
P 0.05 is stringent. Secondary categorical efﬁcacy end-
points were compared between the groups using x
2 tests
and Mann–Whitney U-tests as appropriate.
We used non-linear mixed effect models (NONMEM
VI, Globomax LLC, Hanover, MD, USA) to estimate
population pharmacokinetics, with a Compaq Digital
Fortran Version 6.6A compiler on an Intel Celeron 333
MHz CPU (Intel Corp., Santa Clara, CA, USA) under MS
Windows XP (Microsoft Corp., Seattle, WA, USA). This
model allows assessment of inter-individual variability,
covariance between pharmacokinetic parameters and
residual error. We judged the quality of ﬁt of the pharma-
cokinetic model to data using the NONMEM objective
function examination of plots of observed vs predicted
concentrations and visual predictive checks.
Results
After initial screening, 189 patients were approached; 135
agreed to participate. One to four teeth were extracted
with local anaesthetic alone in 69 patients and with local
anaesthetic in combination with general anaesthesia in 66.
Thirteen patients did not return their patient diaries, so
122 patients were included in the evaluable ITT popu-
lation for the analysis of the primary endpoints (Fig. 1).
The treatment groups were adequately matched in baseline
patient and clinical characteristics (Table 1). Of those in
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extracted compared with 43.6% for ibuprofen and 53.5%
for acetaminophen.
Efﬁcacy
The time-adjusted AUCs were substantially and signiﬁ-
cantly lower at rest and on activity in the combination
group than in either of the other two treatment groups
(Table 2, Figs 2 and 3), with all four P,0.01. The consist-
ency of the treatment effects across strata was conﬁrmed
from the GLM with P-values for the treatment stratum
interaction of 0.955 and 0.984 for time-adjusted AUCs at
rest and on activity, respectively. The type of anaesthetic
(local vs general) and number of teeth extracted did not
change the outcome of either analysis.
Although all four secondary endpoints favour the com-
bination treatment (Table 3), only the global pain rating
reached statistical signiﬁcance. More participants experi-
enced ‘nil’ or ‘mild’ pain with the combination (68.4%)
than with either other group; this difference was signiﬁcant
for acetaminophen (37.5%; P¼0.008), but not for ibupro-
fen (54.3%; P¼0.263). The use of any rescue medication
also favoured the combination treatment (Table 4), but this
did not reach statistical signiﬁcance.
Pharmacokinetics
There were no signiﬁcant differences between the combi-
nation group and either constituent group in any of the
estimated pharmacokinetic parameters (Table 5). The
visual predictive plots of individual concentration showed
that  90% of the observations were within the 90% pre-
diction intervals.
Twelve participants were given both acetaminophen and
ibuprofen. For calculation of the pharmacokinetic vari-
ables, a scaling factor was applied to clearance and
volume of distribution in turn for those participants receiv-
ing the combination of acetaminophen and ibuprofen. This
scaling factor had no impact on either acetaminophen or
ibuprofen pharmacokinetic parameters, indicating that
there was no pharmacokinetic interaction between acetami-
nophen and ibuprofen when administered together
(P.0.05).
Clearance (CL/F) and volume of distribution (V/F) par-
ameters observed in the study are consistent with those
reported previously (acetaminophen: CL/F¼12.6–21.0
litre h
21 70 kg
21, V/F¼48.3–71.0 litre 70 kg
21; ibupro-
fen: CL/F¼2.9–5.9 litre h
21 70 kg
21, V/F¼6.4–23.5 litre
70 kg
21).
18–20
Adverse effects
The frequency of adverse effects was consistent with the
known effects of the constituent drugs, and there were no
Screened
(n =189)
Randomized
(n =135)
Acetaminophen
treatment
group
(n =47)
Ibuprofen
treatment group
(n =44)
Combination
treatment group
(n =44)
Patient diaries
not returned
(n =4)
Patient diaries
not returned
(n =5)
Patient diaries
not returned
(n =4)
Included in the
analysis
(n =43)
Included in the
analysis
(n =39)
Included in the
analysis
(n =40)
Fig 1 Flow of participants through trial. Not randomized (n¼54): (i)
declined to participate (n¼15), (ii) did not meet inclusion criteria
(n¼14), (iii) other reasons (n¼25); other reasons: the surgery was
cancelled or rescheduled; patient could not be contacted; patient was
given the wrong date of the surgery.
Table 1 Patient characteristic and baseline information (SD)
Acetaminophen (n547) Ibuprofen (n544) Combination (n544)
Age [mean (range)] (yr) 23.5 (16.0–40.4) 23.7 (16.8–38.9) 25.0 (18.3–40.4)
Weight [mean (SD)] (kg) 71.3 (15.6) 80.8 (20.1) 71.1 (13.5)
Ethnicity [n (%)]
Asian 4 (8.5) 1 (2.3) 2 (4.5)
Black 1 (2.1) 0 (0.0) 1 (2.3)
Caucasian 33 (70.2) 31 (70.5) 34 (77.3)
Maori 4 (8.5) 4 (9.1) 4 (9.1)
Paciﬁc Islander 4 (8.5) 5 (11.4) 2 (4.5)
Other 1 (2.1) 3 (6.8) 1 (2.3)
Male [n (%)] 13 (27.7) 21 (47.7) 13 (29.5)
Shift workers [n (%)] 10 (21.3) 5 (11.4) 3 (6.8)
Preoperative pain scores at rest [mean (SD)] (mm) 1.9 (5.1) 2.1 (5.2) 2.6 (6.8)
Preoperative pain scores on activity [mean (SD)] (mm) 4.1 (13.3) 2.7 (8.3) 2.9 (6.6)
Sleep disturbance for night before surgery as VAS [mean (SD)] (mm) 64.7 (22.9) 69.1 (26.0) 71.5 (24.1)
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83deﬁnitive indications that the adverse event proﬁle is
changed when the two drugs are combined (Table 6);
however, the numbers were too small to make meaningful
comparisons between the groups. Two participants experi-
enced postoperative bleeding (attributed to surgical
causes), which resolved without readmission to hospital.
No gastrointestinal bleeding was reported during the study.
Most adverse events were evaluated as mild (57.4%) or
moderate (35.2%) and on review were considered not
related (17.5%) or unlikely to be related (66.7%) to study
medication.
General
The majority of participants rated the experience of taking
part in the study as very positive (31%) or positive (47%)
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Fig 2 Mean (þ95% CI) mm of time-adjusted AUC (AUC/time) for VAS
at rest and on activity by treatment group.
Table 2 Mean (SEM, 95% CI) of time-adjusted AUC of visual analogue pain
scores at rest and on activity by treatment group. The differences between
combination and each constituent were signiﬁcant at rest (vs acetaminophen
P¼0.007 and vs ibuprofen P¼0.003) and on activity (vs acetaminophen
P¼0.006 and vs ibuprofen P¼0.007)
Acetaminophen
(n543)
Ibuprofen (n539) Combination
(n540)
At rest 33.0 (3.1, 27.9–38.1) 34.8 (3.2, 29.4–40.2) 22.3 (3.2, 17.0–27.7)
On
activity
40.4 (3.3, 35.0–45.8) 40.2 (3.4, 34.6–45.9) 28.4 (3.4, 22.8–34.1)
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Fig 3 Mean (SE) mm VAS out of 100 at rest (A) and on activity (B).
Table 3 Secondary efﬁcacy endpoints by treatment group. The only
signiﬁcant difference was between the global pain ratings for combination and
acetaminophen (P¼0.008, Mann–Whitney U-test)
Acetaminophen Ibuprofen Combination
Global pain rating [n (%)]
Nil 3 (7.5) 4 (11.4) 4 (10.5)
Mild 12 (30.0) 15 (42.9) 22 (57.9)
Moderate 22 (55.0) 14 (40.0) 12 (31.6)
Severe 3 (7.5) 2 (5.7) 0 (0.0)
Global nausea rating [n (%)]
Nil 26 (65.0) 25 (71.4) 30 (79.0)
Mild 10 (25.0) 8 (22.9) 7 (18.4)
Moderate 3 (7.5) 2 (5.7) 1 (2.6)
Severe 1 (2.5) 0 (0.0) 0 (0.0)
Vomiting episodes (n) 5 (in 3 subjects) 0 0
Sleep disturbance night
1 vs baseline VAS
[mean (SD)] (mm)
221.9 (29.2) 217.4 (22.9) 216.6 (24.7)
Sleep disturbance night
2 vs baseline VAS
[mean (SD)] (mm)
213.7 (32.9) 29.6 (25.8) 28.5 (20.1)
Table 4 Rescue analgesia by group, n (%); none of these differences were
signiﬁcant
Rescue analgesic Acetaminophen Ibuprofen Combination
Fentanyl in hospital 5 (11.6%) 9 (23.7%) 6 (15.4%)
Codeine in the ﬁrst 24 h 21 (47.70%) 16 (43.20%) 13 (32.50%)
Codeine in the second 24 h 22 (53.70%) 14 (42.40%) 16 (42.10%)
Any rescue medication over 48 h 25 (62.5%) 18 (58.10%) 21 (56.8%)
Table 5 Mean (SD) pharmacokinetic parameters (individual Bayesian
estimates used for descriptive statistics) for a one-compartment, ﬁrst-order
absorption, ﬁrst-order elimination model; none of the differences for
combination formulations was signiﬁcant. CL/F, clearance; V/F, volume of
distribution; Tabs, absorption half-time; Cmax, maximum concentration; Tmax,
time to achieve Cmax
Acetaminophen
alone (n515)
Acetaminophen
in combination
(n512)
Ibuprofen
alone
(n511)
Ibuprofen in
combination
(n512)
CL/F (litre
h
21)
14.1 (2.6) 14.2 (1.8) 3.9 (1.7) 3.8 (1.3)
V/F (litre) 55.7 (19.4) 48.2 (18.3) 10.6 (2.1) 9.8 (1.5)
Tabs (h) 0.42 (0.76) 0.16 (0.10) 0.58 (0.78) 0.85 (0.85)
Tmax (h) 1.09 (1.12) 0.64 (0.31) 1.16 (0.90) 1.44 (0.93)
Cmax (mg
litre
21)
15.8 (6.5) 19.2 (6.4) 20.8 (8.3) 19.1 (7.8)
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(3%) found the experience negative, and none rated it as
very negative. The ratings were not signiﬁcantly different
between the study groups.
Discussion
We found that patients using the combination of acetami-
nophen and ibuprofen experienced less pain during the
ﬁrst 48 h after oral surgery than those using the same
daily dosage of either agent alone and we think the differ-
ence was clinically relevant. There was no evidence of any
pharmacokinetic interaction between acetaminophen and
ibuprofen. Patients receiving ibuprofen alone reported the
lowest frequency of adverse events, but the numbers are
too small for meaningful comparisons between the groups,
and we saw no cause for concern in any group.
Our data are consistent with previous evidence showing
that a combination of ibuprofen and acetaminophen pro-
vides better analgesia than acetaminophen alone.
8 9 13 21
Note, however, that two of these studies were in children,
91 3
so data in adults are relatively limited. On the other hand,
there are many studies supporting the more general point
that the addition of various NSAIDs improves the pain
relief obtainable from acetaminophen alone. More impor-
tantly, our data add convincingly to the sparse evidence
supporting the more controversial proposition that this
combination is superior to ibuprofen alone.
12 In a smaller
study in an orthopaedic pain model (which was positive
for the combination in comparison with acetaminophen),
Dahl and colleagues
8 showed no such beneﬁt whereas
Viitanen and colleagues
13 (in a paediatric tonsillectomy
study) showed an advantage for the combination only in
the period after discharge from hospital. The similarity in
efﬁcacy between ibuprofen and acetaminophen on their
own seen in our study contrasts with the ﬁndings of
superior pain relief from ibuprofen after dental surgery by
Cooper and colleagues,
22 but theirs was a single-dose
study.
Limitations and strengths of the study
Our results are limited to adults, and to the doses and
model of pain studied. We think our conclusions are likely
to apply to other age groups and other types of pain, but
this will require conﬁrmation. We have not explored the
optimal dosage of the combination drug, but the dosage
used is consistent with current clinical practice. The
inclusion of patients who underwent both general and
local anaesthesia implies that our ﬁndings are likely to
apply in either case. It is not possible to draw ﬁrm con-
clusions on the safety of any drug from a study of only 40
participants per group, but acetaminophen and ibuprofen
are well established, widely used, and considered very safe
in appropriate doses.
32 3There is no theoretical reason,
Table 6 Adverse events and their relationship with study medication as evaluated by the investigators. Postoperative pain was noted as a complication in 2, 0,
and 1 patient in the acetaminophen, ibuprofen, and combination groups, respectively. Some individuals experienced more than one adverse event
Relationship System organ class Acetaminophen Ibuprofen Combination Total
Not related Gastrointestinal disorders (numbness of tongue) 1 0 0 1
General disorders and administration site conditions (swollen arm, infusion site
phlebitis)
00 2 2
Infections and infestations (dry socket, alveolitis of jaw) 1 0 1 2
Injury, poisoning, and procedural complications (bruising of arm, postoperative
pain)
00 2 2
Musculoskeletal and connective tissue disorders (jaw stiffness) 0 0 1 1
Skin and s.c. tissue disorders (swelling face) 1 1 0 2
Subtotal 31 6 1 0
Unlikely related Blood and lymphatic system disorders (swollen glands) 1 0 0 1
Ear and labyrinth disorders (pain in ear, tinnitus) 2 0 0 2
Gastrointestinal disorders (vomiting, nausea, stomach cramps, dry lips) 6 1 2 9
Injury, poisoning, and procedural complications (postoperative bleeding) 0 0 1 1
Musculoskeletal and connective tissue disorders (jaw stiffness, aches and pains in
legs, jaw pain)
20 1 3
Nervous system disorders (headache, felt faint, sleepy, balance difﬁculty, light
headiness, dizziness, drowsiness, lethargic)
64 4 1 4
Psychiatric disorders (disorientation) 0 1 0 1
Respiratory, thoracic, and mediastinal disorders (sore throat, pharyngeal ulceration,
hypoventilation, coughing)
11 2 4
Investigations (body temperature increased) 0 0 1 1
Skin and s.c. tissue disorders (rash, redness of external ear, swelling face) 0 1 1 2
Subtotal 18 8 12 38
Possibly related Gastrointestinal disorders (stomach cramps, abdominal pain, constipation, stomach
ache, vomiting)
30 2 5
General disorders and administration site conditions (fever) 1 0 0 1
Injury, poisoning, and procedural complications (postoperative bleeding) 0 0 1 1
Nervous system disorders (sleepy, headache) 1 0 1 2
Subtotal 50 4 9
Total 26 9 22 57
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85and no empirical suggestion from our data, to suggest that
the combination would be any less safe than the constitu-
ent drugs on their own. Our safety data are observational
rather than based on prospective laboratory investigations,
but we followed up participants for adverse events for 3
weeks, and it seems unlikely that clinically important
harm would have been missed.
Pain after oral surgery can persist for several days,
10 but
we considered 48 h to be a clinically relevant period, and
a longer period of study is likely to have resulted in poorer
compliance with data collection.
It could be asked whether a more typical (albeit
complex) regimen for ibuprofen alone might have pro-
vided better analgesia than seen with the 4 hourly
approach used here, but this seems unlikely, particularly
given that our clinical efﬁcacy data were supported by esti-
mates of population pharmacokinetics. We had planned to
correlate drug plasma concentration with pain scores, but
the drug plasma concentration results were too sparse and
there were too many confounding variables (such as ethni-
city, comparators, and rescue analgesia) for this to be
undertaken. We did demonstrate a lack of interaction
between the constituent drugs when used in combination
and provided evidence that equivalent and predicted blood
concentrations were achieved (the observations of time–
concentration proﬁle decreased within 90% of prediction
limits for both acetaminophen and ibuprofen). Furthermore,
pharmacokinetic parameter estimates observed in the current
study are very similar to those previously reported.
18–20
The evaluations used in the efﬁcacy analysis have
established construct validity and are appropriate for
parametric analysis.
24 25
In designing analgesic studies, it is an advantage to
minimize the exposure of participants to inadequate
analgesia while controlling for various sources of bias.
Some designs incorporate a placebo group, but the efﬁcacy
of both ibuprofen
26 and acetaminophen
27 in comparison
with placebo are well established by previous research,
and we would argue that the use of a placebo in this situ-
ation is unnecessary and perhaps even unethical.
28 There
would be little value in another ‘me too’ analgesic unless
it had clear advantages over established agents. Therefore,
the question of interest lies in the comparisons between
the new agent (Maxigesic
w) and the reference standard of
care, and in this case, we have actually shown superiority to
both of two possible reference standards—acetaminophen
alone and ibuprofen alone. One classic approach to analgesic
studies involves treating established acute pain. This has the
alleged advantage that pain relief can be assessed (e.g. by
using AUC to estimate total pain relief, or TOTPAR,
29 30 or
by calculating a pain reduction index per tablet).
31 Our
design, in contrast, follows the widely accepted clinical prac-
tice of anticipating and treating pain before it occurs, which,
in our unit at least, has long been considered best practice.
Furthermore, rescue medication was readily available and
those requiring it were evenly distributed between the
groups. It is notable that most patients did require rescue
medication, suggesting that pain after oral surgery can some-
times be severe enough that even the combination of ibupro-
fen and acetaminophen requires supplementation (and it
might be asked whether it would be a good idea for codeine,
for example, to be added to the combined formulation).
Nevertheless, we think it important that the vast majority of
the participants in all groups reported pain scores that were
reasonably low, and that all received analgesic regimens
accepted in contemporary practice. The predominantly posi-
tive evaluation by participants of their experience in taking
part in the study provides empirical reassurance on this point
(and also other aspects of the conduct of the study).
The treatment of pain is central to medical practice in
hospitals and in primary care. If these results are con-
ﬁrmed in other settings, the already widely used combi-
nation of acetaminophen and ibuprofen may become the
standard of care for the initial management of moderate
acute pain, at least for those patients who do not have
contra-indications to NSAIDs. Even using the drugs indi-
vidually, the dosage regimen studied here is simpler than
that currently recommended, and may well improve com-
pliance with and therefore success with this combination.
Providing both drugs in one tablet simpliﬁes this regimen
even further, and our data conﬁrm that the speciﬁc formu-
lation studied here is effective, and that there is no inter-
action between its constituent drugs.
Conclusions
Doctors treating pain after oral surgery, in hospital and at
home, and probably pain in many other situations, should
consider using acetaminophen and ibuprofen together four
times a day, provided there are no contraindications to
either drug, and taking into account the known risks of
NSAIDs. The combination formulation studied here sim-
pliﬁes this regimen.
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